Ann: Updated Strategy and Investor Presentation, page-376

The issue with the EMD AML trial is that it required clinicians to screen their patients for EMD before they failed their current treatment. While they said they would do this, in practice they weren’t willing to do this as PET scanning is not standard-of-care in AML. It didn’t matter that they have no idea if their patients have EMD or not and the risk to the patient of a PET scan is near zero, if it is not standard-of-care then it is not done outside of a clinical trial.

The upcoming cardioprotection trial is different in that the way it is run is 100% standard-of-care the whole way so the clinicians don’t need to do anything that is outside of the guidelines.

Having said all this I expect PET scanning AML patients for EMD will be standard-of-care in a few years time just like minimal residual disease screening was outside the guidelines right up until the day it became standard-of-care.